TITLE

PHOTOCURE SIGNS NEW PACT WITH NORWEGIAN RADIUM HOSPITAL

PUB. DATE
April 2003
SOURCE
Worldwide Biotech;Apr2003, Vol. 15 Issue 4, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents details on a three-year research collaboration between PhotoCure ASA with the Norwegian Radium Hospital Research Foundation, as of April 2003.
ACCESSION #
9427681

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;4/11/2013, Vol. 24 Issue 69, p3 

    The article offers world news briefs in 2013. The U.S. approves BioLineRx Ltd. to commence its Phase IIa antagonist BL-8040 trial for acute myeloid leukemia (AML). It notes that Kwang Dong Pharmaceutical Co. Ltd. and Laboratorios Salvat SA has completed Phase IIb trial of Tarafenacin for...

  • Photocure gets financing from Ipsen.  // Medical Device Daily;3/6/2012, Vol. 16 Issue 44, p3 

    The article reports that Photocure has received a second manufacturing transition milestone payment from Ipsen, its strategic partner for commercializing Hevvix worldwide.

  • Light switch. Czyzewski, Andrew // Engineer (00137758);3/28/2011, Vol. 296 Issue 7813, p12 

    The article offers brief information on the Cervira photodynamic therapy (PDT)-based system from Sagentia and Photocure ASA.

  • Clinic Roundup.  // BioWorld Today;1/27/2011, Vol. 22 Issue 18, p5 

    This section offers news briefs on clinical trials, including ChemoCentryx Inc.'s Phase I trial of CCX832, an oral, small-molecule inhibitor of ChemR23 aimed at treating psoriasis, the Phase II results for Photocure ASA's photodynamic therapy Cevira, and positive results from Resverlogix Corp.'s...

  • People in the News.  // Medical Device Daily;7/6/2012, Vol. 16 Issue 130, p2 

    The article announces the appointment of Erik Gahl as chief financial officer (CFO) of Photocure, effective August 15, 2012.

  • Phase II success. Robinson, Kevin // Pharmaceutical Technology Europe;Oct2001, Vol. 13 Issue 10, p10 

    Reports on the success of Phase II clinical trials for Hexvix, a tool for the diagnosis of bladder cancer, developed by PhotoCure ASA. Significance of the outcome of the clinical trials for the company; Details of the clinical trials; Comparison between the results of Hexvix fluorescence...

  • Photocure Preps for Phase III With HPV PTD Therapy Cervira. Moran, Nuala // BioWorld International;4/17/2013, Vol. 18 Issue 16, p3 

    The article reports that biopharmaceutical firm Photocure ASA is preparing its photodynamic therapy (PDT) Cervira for Phase III trial. Photocure released positive results from its Phase IIb trial of PDT Servira in treating oncogenic human papillomavirus (HPV) infections and pre-cancerous lesions...

  • Hexvix: Hexvix Pd, Hexvix Pdt.  // Drugs in R&D;2003, Vol. 4 Issue 2, p128 

    Provides information on the drug Hexvix from PhotoCure for the diagnosis and treatment of bladder cancer. Investigation into its effectiveness in the diagnosis of cervical cancer, vulvae cancer and some gynaecological conditions; Approval of PhotoCure's patent application covering...

  • Hexvix: Hexvix Pd, Hexvix Pdt.  // Drugs in R&D;2003, Vol. 4 Issue 2, p128 

    Provides information on Hexvix, a drug from PhotoCure for the diagnosis and treatment of bladder cancer. Procedure for diagnosis of cervical cancer, vulvae cancer and some gynaecological conditions; Patent information; Drug development history.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics